Make Informed Investment Decisions with Affordable Access to Experts
A discussion on the potential of Lannett's (LCI) generic chemo agent temozolomide capsules to gain a portion of Merck's (MRK) market share for temodar in a certain type of brain tumorTicker(s): MRK, LCI
An expert with significant experience treating patients with this type of brain tumor who has deep knowledge of the labels, data, and profiles for temodar and temozolomide.
Can you describe your experience treating patients with this type of brain tumor and your knowledge of the labels, data, and profiles of temodar and temozolomide?Added By: pjloria
Are there any significant differences in the labels, data, and profiles for temodar and the generic capsul temozolomide?Added By: pjloria
How many patients would you estimate are in the market for this particular type of brain tumor?Added By: pjloria
What are the pricing differences for temodar and temozolomide?Added By: pjloria
What percentage of patients do you think will use temozolomide over temodar going forward?Added By: pjloria
Why would a patient choose temodar over temozolomide?Added By: pjloria
Is there potential for patients who are currently taking temodar to switch to temozolomide?Added By: pjloria
What obstacles will Lannett face in marketing temozolomide?Added By: pjloria
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
- Lannett Receives FDA Approval For Temozolomide Capsules LCI Occurred On: Feb 11, 2016